Harold Bernstein Sells 5,106 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 5,106 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total transaction of $135,155.82. Following the sale, the chief marketing officer owned 14,894 shares in the company, valued at $394,244.18. This represents a 25.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Harold Bernstein also recently made the following trade(s):

• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $134,965.89.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Trading Up 1.3%

Shares of NASDAQ:MAZE traded up $0.34 on Friday, hitting $26.21. 273,266 shares of the company’s stock were exchanged, compared to its average volume of 637,671. The business’s 50 day simple moving average is $28.74 and its two-hundred day simple moving average is $31.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics, Inc. has a 12 month low of $14.27 and a 12 month high of $53.65. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). Analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Maze Therapeutics in the 1st quarter worth approximately $57,000. Goldman Sachs Group Inc. purchased a new stake in shares of Maze Therapeutics in the first quarter worth about $145,000. Rhumbline Advisers acquired a new stake in Maze Therapeutics during the first quarter worth about $80,000. Geode Capital Management LLC grew its holdings in Maze Therapeutics by 8.8% during the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after acquiring an additional 18,773 shares during the period. Finally, Legal & General Group Plc raised its position in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after acquiring an additional 3,371 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have commented on MAZE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $66.00.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.